Technical Analysis for IRWD - Ironwood Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
IRWD closed up 1.17 percent on Tuesday, September 18, 2018, on 76 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
|See historical IRWD trend table...|
|Date||Alert Name||Type||% Chg|
|Sep 18||200 DMA Support||Bullish||0.00%|
|Sep 18||Hammer Candlestick||Bullish||0.00%|
|Sep 18||Lower Bollinger Band Touch||Weakness||0.00%|
|Sep 17||Below Lower BB||Weakness||1.17%|
|Sep 17||Lower Bollinger Band Touch||Weakness||1.17%|
|Sep 14||Spinning Top||Other||-5.36%|
|Sep 14||NR7||Range Contraction||-5.36%|
|Sep 13||Lower Bollinger Band Walk||Weakness||-4.95%|
|Sep 13||Lower Bollinger Band Touch||Weakness||-4.95%|
|Sep 13||Oversold Stochastic||Weakness||-4.95%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company's lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more IRWD news...
|52 Week High||21.2|
|52 Week Low||12.89|
|200-Day Moving Average||16.9858|
|50-Day Moving Average||18.9538|
|20-Day Moving Average||18.334|
|10-Day Moving Average||17.922|
|Average True Range||0.6348|
|Chandelier Exit (Long, 3 ATRs )||17.7356|
|Chandelier Exit (Short, 3 ATRs )||18.7244|
|Upper Bollinger Band||19.5832|
|Lower Bollinger Band||17.0848|
|Percent B (%b)||0.08|
|MACD Signal Line||-0.2554|
|Market Cap||2.59 Billion|
|Num Shares||150 Million|
|Price-to-Earnings (P/E) Ratio||-17.64|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||18.04|
|Resistance 3 (R3)||17.97||17.64||17.92|
|Resistance 2 (R2)||17.64||17.45||17.68||17.87|
|Resistance 1 (R1)||17.47||17.33||17.56||17.54||17.83|
|Support 1 (S1)||16.97||16.95||17.06||17.04||16.75|
|Support 2 (S2)||16.64||16.83||16.68||16.71|
|Support 3 (S3)||16.47||16.64||16.67|
|Support 4 (S4)||16.54|